Case Report

Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule”

Jennifer E. Vaughn1 and Ajay K. Gopal1,2,3

1 Department of Internal Medicine, University of Washington, Box 39892. 325 Ninth Ave., Seattle, WA 98104, USA
2 Clinical Research Division, Fred Hutchinson Research Center, Seattle, WA, USA
3 Seattle Cancer Care Alliance, Mailstop G6-800, 825 Eastlake Ave. E Seattle, WA 98109, USA

Correspondence should be addressed to Jennifer E. Vaughn, jev5@u.washington.edu

Received 6 January 2010; Accepted 25 February 2010

1. Introduction

Umbilical malignant metastasis is a rare sign of advanced malignancy and usually associated with cancers of the gastrointestinal and reproductive tract [1]. The term “Sister Mary Joseph’s nodule” was coined by Sir Hamilton Bailey, after Sister Mary Joseph Dempsey (1856–1939) who served as surgical assistant to Dr. William Mayo in Rochester, MN. She was the first to observe the association between umbilical nodules, which she named “pants button umbilicus,” and metastatic intraabdominal disease. This discovery was published in 1928 [2]. As was also noted by its namesake, it is generally thought to signify a poor prognosis, with mean survival reported between 8 and 11 months [1, 3, 4].

Interestingly, reports of hematological malignancies presenting in this manner are exceedingly uncommon and when reported, do not necessarily represent intractable disease. In a review of 407 cases of SMJ nodules, only 1 was noted to be of lymphomatous origin [5, 6]. Further review of the literature revealed five cases of SIM nodules determined to be from metastatic lymphoma [5–10] with four demonstrating significant responses to chemotherapy [7–10] and two [7, 8] achieving complete remission. All five case reports identified the malignancy as non-Hodgkin lymphoma and two of these were specifically identified as large B-cell lymphomas [8, 9]. None were of MCL origin. In fact, a dedicated search revealed no cases of MCL presenting as SMJ nodule in the literature.

2. Case Report

A 72-year-old male with a history of previously treated blastic variant (Ki-67 60%–70%) mantle cell lymphoma (MCL) presented to his outpatient oncology clinic with new complaints consisting of diffuse abdominal pain and distention, night sweats, fatigue, and a new mass within the umbilicus. The patient was noted to have a Mantle Cell Lymphoma International Prognostic Index (MIPI) [11] of 6, primarily receiving a high risk score due to age >70 and an LDH which was 1.4 times the upper limit of normal. The patient’s performance status was limited only by weakness attributed to chronic narcotic use, but he was otherwise very functional at the time of presentation.

Recurrence was noted by PET scan to have occurred in areas of previous involvement, including several areas above
the diaphragm, the retroperitoneum, and the right pelvis. However, abdominal examination revealed a new, nontender, violaceous mass projecting from the umbilicus (Figure 1). Computerized tomography of the chest, abdomen and pelvis confirmed the presence of the lesion within the umbilical cavity and also demonstrated an abdominal mass measuring 20.7 cm × 30 cm × 13 cm abutting the stomach against the diaphragm (Figure 2). This constellation of findings was thought to represent relapsed MCL and the protuberant abdominal mass consistent with the finding of a Sister Mary Joseph’s (SMJ) nodule. The patient experienced multiple relapses after R-CHOP, single agent rituximab, bortezomib, and gemcitabine-carboplatin-dexamethasone-rituximab. Following this most recent relapse, he experienced a transient response to cyclophosphamide, etoposide, dexamethasone, and rituximab, but unfortunately expired 11 months later after further tumor progression.

3. Discussion

MCL is characterized by frequent extranodal involvement with a predilection to the aerodigestive tract, though ocular, central nervous system, breast, skin, and testicular involvement have been reported [12–17]. Studies meant to characterize the frequency of spread to these sites are often limited by low case numbers and methodology of patient selection. Clinically significant gastrointestinal involvement has been historically reported in 15%–30% of cases [18–21] although studies of random biopsy specimens from the GI tracts of untreated MCL patients suggest that this number may much higher [18, 22]. Central nervous system (CNS) infiltration has been described in anywhere of 2%–23% of MCL patients [15, 23, 24] and was associated with high tumor proliferative rate, blastic variant, and elevated lactate dehydrogenase [25]. Factors associated with other sites of extranodal disease beyond the gastrointestinal tract, bone marrow, and CNS are less well described but are also likely correlated with these same factors.

In general, MCL is characterized by lack of sustained responses to conventional therapies and poorer outcomes when compared to other lymphomas. While five-year survival after standard R-CHOP therapy was recently demonstrated to have improved from 22% to 47% [26], worse outcomes are associated with the presence of >1 extranodal site of disease [20, 27]. This case presentation illustrates both another unusual extranodal manifestation of MCL and the still grave prognosis of this entity emphasizing the need for more effective treatments.

Acknowledgements

Research Support: The Lymphoma Research Foundation Mantle Cell Lymphoma Research Initiative, The Mary A. Wright memorial research fund, and a donation from Frank and Betty Vandermeer. AKG is a scholar in clinical research of the leukemia and lymphoma society.

References

[1] M. V. Barrow, “Metastatic tumours of the umbilicus,” Journal of Chronic Disease, vol. 19, pp. 1113–1117, 1996.
[2] D. Trebing and H.-D. Göring, “Die nabelmetastase. Sister Mary Joseph und ihre Zeit,” Der Hautarzt, vol. 55, no. 2, pp. 186–189, 2004.
[3] A. Dubreuil, A. Dompmartin, P. Barjot, S. Louvet, and D. Leroy, “Umbilical metastasis or Sister Mary Joseph’s nodule,” International Journal of Dermatology, vol. 37, no. 1, pp. 7–13, 1998.
[4] F. C. Powell, A. J. Cooper, M. C. Massa, et al., “Sister Mary Joseph’s nodule: a clinical and histologic study,” Journal of the American Academy of Dermatology, vol. 10, no. 4, pp. 610–615, 1984.
[5] V. G. Galvan, “Sister Mary Joseph’s nodule,” Annals of Internal Medicine, vol. 128, no. 5, p. 410, 1998.
[6] K. Nagao and A. Kikuchi, “Sister Joseph’s node in non-Hodgkin’s lymphoma,” The New England Journal of Medicine, vol. 335, no. 21, p. 1569, 1996.
[7] C. Tam, H. Turner, R. J. Hicks, and J. F. Seymour, “Diffuse large B-cell non-Hodgkin’s lymphoma presenting as Sister Joseph’s nodule,” Leukemia and Lymphoma, vol. 43, no. 10, pp. 2055–2057, 2002.
[8] A. Chagpar and J. W. Carter, “Lymphoma presenting as a Sister Mary Joseph’s nodule,” American Surgeon, vol. 64, no. 8, pp. 799–800, 1998.
[9] M. C. Thomas and G. M. Jeffery, “Sister Joseph’s nodule in non-Hodgkin’s lymphoma,” Clinical Oncology, vol. 10, no. 5, pp. 322–323, 1998.
[10] U. Handa, S. Garg, and H. Mohan, “Fine-needle aspiration cytology of Sister Mary Joseph’s (Paraumbilical) nodules,” *Diagnostic Cytopathology*, vol. 36, no. 5, pp. 348–350, 2008.

[11] E. Hoster, M. Dreyling, W. Klapper, et al., “A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma,” *Blood*, vol. 111, no. 2, pp. 558–565, 2008.

[12] I. Sabnani, J. Varughese, R. Wascher, H. Youngworth, and P. Tsang, “Multiple synchronous unusual extranodal sites of relapse in a patient with mantle cell lymphoma,” *Clinical Advances in Hematology and Oncology*, vol. 5, no. 10, pp. 797–802, 2007.

[13] E. Iwuanyanwu, L. J. Medeiros, J. E. Romaguera, and L. E. Fayad, “Mantle cell lymphoma with a rare involvement of the testicle,” *Leukemia and Lymphoma*, vol. 48, no. 6, pp. 1242–1243, 2007.

[14] A. Dean, T. E. Rogers, J. Diehl, et al., “Extradural sites of involvement in hematologic malignancies: case 1. Multifocal intracranial involvement with mantle-cell lymphoma,” *Journal of Clinical Oncology*, vol. 20, no. 1, pp. 340–342, 2002.

[15] R. Valdez, S. H. Kroft, C. W. Ross, et al., “Cerebrospinal fluid involvement in mantle cell lymphoma,” *Modern Pathology*, vol. 15, no. 10, pp. 1073–1079, 2002.

[16] J. A. Ferry, C. Y. Fung, L. Zukerberg, et al., “Lymphoma of the ocular adnexa: a study of 353 cases,” *American Journal of Surgical Pathology*, vol. 31, no. 2, pp. 170–182, 2007.

[17] S.-I. Motegi, E. Okada, Y. Nagai, A. Tamura, and O. Ishikawa, “Skin manifestation of mantle cell lymphoma,” *European Journal of Dermatology*, vol. 16, no. 4, pp. 435–438, 2006.

[18] J. E. Romaguera, L. J. Medeiros, F. B. Hagemeister, et al., “Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma,” *Cancer*, vol. 97, no. 3, pp. 586–591, 2003.

[19] A. J. Norton, J. Matthews, V. Pappa, et al., “Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period,” *Annals of Oncology*, vol. 6, no. 3, pp. 249–256, 1995.

[20] H. Samaha, C. Dumontet, N. Ketterer, et al., “Mantle cell lymphoma: a retrospective study of 121 cases,” *Leukemia*, vol. 12, no. 8, pp. 1281–1287, 1998.

[21] P. Meusers, J. Hense, and G. Brittinger, “Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems,” *Leukemia*, vol. 11, supplement 2, pp. s60–s64, 1997.

[22] A. Salar, N. Juanpere, B. Bellosillo, et al., “Gastrointestinal involvement in mantle cell lymphoma: a prospective clinical, endoscopic, and pathologic study,” *American Journal of Surgical Pathology*, vol. 30, no. 10, pp. 1274–1280, 2006.

[23] R. Oinonen, K. Franssila, and E. Elonen, “Central nervous system involvement in patients with mantle cell lymphoma,” *Annals of Hematology*, vol. 78, no. 3, pp. 145–149, 1999.

[24] E. Montserrat, F. Bosch, A. Lopez-Guillermo, et al., “CNS involvement in mantle-cell lymphoma,” *Journal of Clinical Oncology*, vol. 14, no. 3, pp. 941–944, 1996.

[25] A. Ferrer, F. Bosch, N. Villamor, et al., “Central nervous system involvement in mantle cell lymphoma,” *Annals of Oncology*, vol. 19, no. 1, pp. 135–141, 2008.

[26] A. Herrmann, E. Hoster, T. Zwingers, et al., “Improvement of overall survival in advanced stage mantle cell lymphoma,” *Journal of Clinical Oncology*, vol. 27, no. 4, pp. 511–518, 2009.

[27] B. T. Hennessy, E. O. Hanrahan, and P. A. Daly, “Non-Hodgkin lymphoma: an update,” *The Lancet Oncology*, vol. 5, no. 6, pp. 341–353, 2004.